MYC and hepatocellular carcinoma: Also of some relevance, metformin was shown to enhance the efficacy of immunotherapies.102 However, mouse models for HCC may have limitations in replicating the entire process of development and metastasis of HCC in humans, as the DEN-HFD and MYC;Trp53−/− HCCs were both non-metastatic, and the Hepa1-6 allografts demonstrate only limited metastatic ability.103,104 In the case of Hepa1-6, aldometanib does not affect the invasiveness or migration of these cells in vitro, nor does it influence the lung metastasis of the allografts in vivo (Supplementary information, Fig. S15i–k).